Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
45
APRE Quote, Financials, Valuation and Earnings
Last price:
$0.89
Seasonality move
:
-26.68%
Day range:
$0.82 - $0.92
52-week range:
$0.55 - $2.79
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
11.46x
P/B ratio:
0.59x
Volume:
110.4K
Avg. volume:
4.3M
1-year change:
-63.33%
Market cap:
$6.4M
Revenue:
$1.5M
EPS (TTM):
-$2.14
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
APRE
Aprea Therapeutics, Inc.
|
-- | -$0.36 | -100% | -25.94% | $5.33 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.6M | $0.14 | 15.84% | -39.95% | $31.80 |
|
ERNA
Ernexa Therapeutics, Inc.
|
-- | -- | -- | -- | -- |
|
MODD
Modular Medical, Inc.
|
-- | -$0.12 | -- | -47.83% | $8.00 |
|
RXRX
Recursion Pharmaceuticals, Inc.
|
$24.6M | -$0.32 | 18.41% | -51.46% | $6.71 |
|
TNGX
Tango Therapeutics, Inc.
|
$500.4K | -$0.33 | -100% | -9.18% | $15.67 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
APRE
Aprea Therapeutics, Inc.
|
$0.92 | $5.33 | $6.4M | -- | $0.00 | 0% | 11.46x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$24.56 | $31.80 | $4.2B | 10.73x | $0.00 | 0% | 3.89x |
|
ERNA
Ernexa Therapeutics, Inc.
|
$0.29 | -- | $2.2M | -- | $0.00 | 0% | 8,421.28x |
|
MODD
Modular Medical, Inc.
|
$0.25 | $8.00 | $19.2M | -- | $0.00 | 0% | -- |
|
RXRX
Recursion Pharmaceuticals, Inc.
|
$3.67 | $6.71 | $1.9B | -- | $0.00 | 0% | 22.04x |
|
TNGX
Tango Therapeutics, Inc.
|
$11.14 | $15.67 | $1.5B | -- | $0.00 | 0% | 18.45x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
APRE
Aprea Therapeutics, Inc.
|
-- | 1.441 | -- | 5.12x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
4.08% | 3.124 | 1.15% | 3.40x |
|
ERNA
Ernexa Therapeutics, Inc.
|
13.39% | 3.180 | 6.85% | 1.42x |
|
MODD
Modular Medical, Inc.
|
7.89% | -2.380 | 1.78% | 1.35x |
|
RXRX
Recursion Pharmaceuticals, Inc.
|
6.45% | 2.185 | 3.66% | 5.06x |
|
TNGX
Tango Therapeutics, Inc.
|
17.85% | 10.129 | 3.71% | 8.31x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
APRE
Aprea Therapeutics, Inc.
|
-$3.6K | -$3.1M | -75.35% | -75.35% | -173188.89% | -$3.3M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257.8M | $17.4M | 41.28% | 43.78% | 6.12% | -$52.7M |
|
ERNA
Ernexa Therapeutics, Inc.
|
-$70K | -$2M | -5889.53% | -- | -226500% | -$1.3M |
|
MODD
Modular Medical, Inc.
|
-$430K | -$7.2M | -233.3% | -248.73% | -- | -$8.4M |
|
RXRX
Recursion Pharmaceuticals, Inc.
|
$8.7M | -$108.3M | -58.45% | -63.64% | -304.84% | -$47.3M |
|
TNGX
Tango Therapeutics, Inc.
|
$53.3M | $14.1M | -46.91% | -56.44% | 26.15% | -$31.1M |
Aprea Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns APRE or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -165133.33% compared to Aprea Therapeutics, Inc.'s net margin of 96.33%. Aprea Therapeutics, Inc.'s return on equity of -75.35% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 43.78%.
Company Gross Margin Earnings Per Share Invested Capital APREAprea Therapeutics, Inc.-200% -$0.47 $11.6M ACADACADIA Pharmaceuticals, Inc.90.77% $1.60 $1.3B -
What do Analysts Say About APRE or ACAD?
Aprea Therapeutics, Inc. has a consensus price target of $5.33, signalling upside risk potential of 481.8%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.80 which suggests that it could grow by 29.48%. Given that Aprea Therapeutics, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Aprea Therapeutics, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings APREAprea Therapeutics, Inc.2 0 0 ACADACADIA Pharmaceuticals, Inc.11 5 1 -
Is APRE or ACAD More Risky?
Aprea Therapeutics, Inc. has a beta of 1.418, which suggesting that the stock is 41.841% more volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.661, suggesting its less volatile than the S&P 500 by 33.872%.
-
Which is a Better Dividend Stock APRE or ACAD?
Aprea Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aprea Therapeutics, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APRE or ACAD?
Aprea Therapeutics, Inc. quarterly revenues are $1.8K, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $284M. Aprea Therapeutics, Inc.'s net income of -$3M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $273.6M. Notably, Aprea Therapeutics, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 10.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aprea Therapeutics, Inc. is 11.46x versus 3.89x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APREAprea Therapeutics, Inc.11.46x -- $1.8K -$3M ACADACADIA Pharmaceuticals, Inc.3.89x 10.73x $284M $273.6M
-
Which has Higher Returns APRE or ERNA?
Ernexa Therapeutics, Inc. has a net margin of -165133.33% compared to Aprea Therapeutics, Inc.'s net margin of -575900%. Aprea Therapeutics, Inc.'s return on equity of -75.35% beat Ernexa Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital APREAprea Therapeutics, Inc.-200% -$0.47 $11.6M ERNAErnexa Therapeutics, Inc.-102.13% -$0.15 $4.1M -
What do Analysts Say About APRE or ERNA?
Aprea Therapeutics, Inc. has a consensus price target of $5.33, signalling upside risk potential of 481.8%. On the other hand Ernexa Therapeutics, Inc. has an analysts' consensus of -- which suggests that it could grow by 315578.55%. Given that Ernexa Therapeutics, Inc. has higher upside potential than Aprea Therapeutics, Inc., analysts believe Ernexa Therapeutics, Inc. is more attractive than Aprea Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings APREAprea Therapeutics, Inc.2 0 0 ERNAErnexa Therapeutics, Inc.0 0 0 -
Is APRE or ERNA More Risky?
Aprea Therapeutics, Inc. has a beta of 1.418, which suggesting that the stock is 41.841% more volatile than S&P 500. In comparison Ernexa Therapeutics, Inc. has a beta of 6.577, suggesting its more volatile than the S&P 500 by 557.698%.
-
Which is a Better Dividend Stock APRE or ERNA?
Aprea Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ernexa Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aprea Therapeutics, Inc. pays -- of its earnings as a dividend. Ernexa Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APRE or ERNA?
Aprea Therapeutics, Inc. quarterly revenues are $1.8K, which are larger than Ernexa Therapeutics, Inc. quarterly revenues of --. Aprea Therapeutics, Inc.'s net income of -$3M is lower than Ernexa Therapeutics, Inc.'s net income of -$1.2M. Notably, Aprea Therapeutics, Inc.'s price-to-earnings ratio is -- while Ernexa Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aprea Therapeutics, Inc. is 11.46x versus 8,421.28x for Ernexa Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APREAprea Therapeutics, Inc.11.46x -- $1.8K -$3M ERNAErnexa Therapeutics, Inc.8,421.28x -- -- -$1.2M
-
Which has Higher Returns APRE or MODD?
Modular Medical, Inc. has a net margin of -165133.33% compared to Aprea Therapeutics, Inc.'s net margin of --. Aprea Therapeutics, Inc.'s return on equity of -75.35% beat Modular Medical, Inc.'s return on equity of -248.73%.
Company Gross Margin Earnings Per Share Invested Capital APREAprea Therapeutics, Inc.-200% -$0.47 $11.6M MODDModular Medical, Inc.-- -$0.11 $6.4M -
What do Analysts Say About APRE or MODD?
Aprea Therapeutics, Inc. has a consensus price target of $5.33, signalling upside risk potential of 481.8%. On the other hand Modular Medical, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 3137.56%. Given that Modular Medical, Inc. has higher upside potential than Aprea Therapeutics, Inc., analysts believe Modular Medical, Inc. is more attractive than Aprea Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings APREAprea Therapeutics, Inc.2 0 0 MODDModular Medical, Inc.1 0 0 -
Is APRE or MODD More Risky?
Aprea Therapeutics, Inc. has a beta of 1.418, which suggesting that the stock is 41.841% more volatile than S&P 500. In comparison Modular Medical, Inc. has a beta of -0.111, suggesting its less volatile than the S&P 500 by 111.096%.
-
Which is a Better Dividend Stock APRE or MODD?
Aprea Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Modular Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aprea Therapeutics, Inc. pays -- of its earnings as a dividend. Modular Medical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APRE or MODD?
Aprea Therapeutics, Inc. quarterly revenues are $1.8K, which are larger than Modular Medical, Inc. quarterly revenues of --. Aprea Therapeutics, Inc.'s net income of -$3M is higher than Modular Medical, Inc.'s net income of -$7.4M. Notably, Aprea Therapeutics, Inc.'s price-to-earnings ratio is -- while Modular Medical, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aprea Therapeutics, Inc. is 11.46x versus -- for Modular Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APREAprea Therapeutics, Inc.11.46x -- $1.8K -$3M MODDModular Medical, Inc.-- -- -- -$7.4M
-
Which has Higher Returns APRE or RXRX?
Recursion Pharmaceuticals, Inc. has a net margin of -165133.33% compared to Aprea Therapeutics, Inc.'s net margin of -304.24%. Aprea Therapeutics, Inc.'s return on equity of -75.35% beat Recursion Pharmaceuticals, Inc.'s return on equity of -63.64%.
Company Gross Margin Earnings Per Share Invested Capital APREAprea Therapeutics, Inc.-200% -$0.47 $11.6M RXRXRecursion Pharmaceuticals, Inc.24.37% -$0.21 $1.2B -
What do Analysts Say About APRE or RXRX?
Aprea Therapeutics, Inc. has a consensus price target of $5.33, signalling upside risk potential of 481.8%. On the other hand Recursion Pharmaceuticals, Inc. has an analysts' consensus of $6.71 which suggests that it could grow by 82.95%. Given that Aprea Therapeutics, Inc. has higher upside potential than Recursion Pharmaceuticals, Inc., analysts believe Aprea Therapeutics, Inc. is more attractive than Recursion Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings APREAprea Therapeutics, Inc.2 0 0 RXRXRecursion Pharmaceuticals, Inc.1 5 0 -
Is APRE or RXRX More Risky?
Aprea Therapeutics, Inc. has a beta of 1.418, which suggesting that the stock is 41.841% more volatile than S&P 500. In comparison Recursion Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock APRE or RXRX?
Aprea Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recursion Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aprea Therapeutics, Inc. pays -- of its earnings as a dividend. Recursion Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APRE or RXRX?
Aprea Therapeutics, Inc. quarterly revenues are $1.8K, which are smaller than Recursion Pharmaceuticals, Inc. quarterly revenues of $35.5M. Aprea Therapeutics, Inc.'s net income of -$3M is higher than Recursion Pharmaceuticals, Inc.'s net income of -$108.1M. Notably, Aprea Therapeutics, Inc.'s price-to-earnings ratio is -- while Recursion Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aprea Therapeutics, Inc. is 11.46x versus 22.04x for Recursion Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APREAprea Therapeutics, Inc.11.46x -- $1.8K -$3M RXRXRecursion Pharmaceuticals, Inc.22.04x -- $35.5M -$108.1M
-
Which has Higher Returns APRE or TNGX?
Tango Therapeutics, Inc. has a net margin of -165133.33% compared to Aprea Therapeutics, Inc.'s net margin of 29.52%. Aprea Therapeutics, Inc.'s return on equity of -75.35% beat Tango Therapeutics, Inc.'s return on equity of -56.44%.
Company Gross Margin Earnings Per Share Invested Capital APREAprea Therapeutics, Inc.-200% -$0.47 $11.6M TNGXTango Therapeutics, Inc.98.97% $0.14 $194.8M -
What do Analysts Say About APRE or TNGX?
Aprea Therapeutics, Inc. has a consensus price target of $5.33, signalling upside risk potential of 481.8%. On the other hand Tango Therapeutics, Inc. has an analysts' consensus of $15.67 which suggests that it could grow by 40.63%. Given that Aprea Therapeutics, Inc. has higher upside potential than Tango Therapeutics, Inc., analysts believe Aprea Therapeutics, Inc. is more attractive than Tango Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings APREAprea Therapeutics, Inc.2 0 0 TNGXTango Therapeutics, Inc.9 1 0 -
Is APRE or TNGX More Risky?
Aprea Therapeutics, Inc. has a beta of 1.418, which suggesting that the stock is 41.841% more volatile than S&P 500. In comparison Tango Therapeutics, Inc. has a beta of 1.761, suggesting its more volatile than the S&P 500 by 76.144%.
-
Which is a Better Dividend Stock APRE or TNGX?
Aprea Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tango Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aprea Therapeutics, Inc. pays -- of its earnings as a dividend. Tango Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APRE or TNGX?
Aprea Therapeutics, Inc. quarterly revenues are $1.8K, which are smaller than Tango Therapeutics, Inc. quarterly revenues of $53.8M. Aprea Therapeutics, Inc.'s net income of -$3M is lower than Tango Therapeutics, Inc.'s net income of $15.9M. Notably, Aprea Therapeutics, Inc.'s price-to-earnings ratio is -- while Tango Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aprea Therapeutics, Inc. is 11.46x versus 18.45x for Tango Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APREAprea Therapeutics, Inc.11.46x -- $1.8K -$3M TNGXTango Therapeutics, Inc.18.45x -- $53.8M $15.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
54
AAOI alert for Mar 2
Applied Optoelectronics, Inc. [AAOI] is up 21.71% over the past day.
Buy
90
BNAI alert for Mar 2
Brand Engagement Network, Inc. [BNAI] is up 2.44% over the past day.
Sell
36
WLDN alert for Mar 2
Willdan Group, Inc. [WLDN] is down 1.93% over the past day.
